BioSpace News Archive

Evelo Biosciences, Inc., a clinical stage biotechnology company developing a novel platform of orally delivered medicines acting on the small intestinal axis, SINTAX, announced that it will host a conference call and live webcast at 7:30 a.m. ET on Thursday, August 11, 2022, to report its second quarter 2022 financial results.

Nuvalent, Inc. announced new preclinical data supporting the potential best-in-class profile of NVL-655 – an ALK-selective inhibitor, and a “Trial in Progress” poster for the Phase 1/2 ARROS-1 study of NVL-520 – a ROS1-selective inhibitor.

Click Therapeutics, Inc. (“Click”), a leader in Digital Therapeutics™ as prescription medical treatments, today announced that Randall Stanicky, Chief Financial Officer, will present at the Canaccord Genuity 42nd Annual Growth Conference on Thursday, August 11, 2022 at 12:30 p.m. ET.

Forma Therapeutics Holdings, Inc. (Nasdaq: FMTX), a clinical-stage biopharmaceutical company focused on sickle cell disease, prostate cancer and other rare hematologic diseases and cancers, today reported financial results for the second quarter ended June 30, 2022.

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company developing innovative therapies designed to treat immune-mediated diseases, today reported recent corporate highlights and financial results for the quarter ended June 30, 2022.

Acerus Pharmaceuticals Corporation (the “ Company ” or “ Acerus ”) (TSX:ASP; OTCQB:ASPCF) today announced that it has entered into an amending agreement with First Generation Capital Inc. (“ First Generation ”), a company affiliated with the Chairman of the Board of Directors of Acerus 1 , to increase its existing secured loan facility (the “ Loan Facility ”) from US$37.945 million to US$47.945 million.

Arch Biopartners Inc. announced today that the Company has added Dr. David Luke as a Strategic Advisor for the clinical trial development of the Company’s drug candidates.

Humacyte, Inc. will release its financial results for the second quarter ended June 30, 2022, on Friday, August 12, 2022.

Wilmington, Delaware, United States, Transparency Market Research Inc. – Gastrointestinal bleeding is also known as gastrointestinal hemorrhage.

Fact.MR – A Market Research and Competitive Intelligence Provider: The global fiducial market is predicted to witness a CAGR of 8% during the forecast period.